A Phase 1, Single Centre, Open Label, Crossover Study in Healthy Volunteers Using Scintigraphy to Evaluate the Gastrointestinal Behaviour of EDP1815 Oral Dosage Forms
Latest Information Update: 27 Mar 2023
At a glance
- Drugs EDP-1815 (Primary)
- Indications Atopic dermatitis; COVID 2019 infections; Inflammation; Psoriasis
- Focus Pharmacokinetics
- Sponsors Evelo Biosciences
Most Recent Events
- 23 Mar 2023 Status changed from active, no longer recruiting to completed.
- 28 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2022 Planned number of patients changed from 24 to 48.